Finance

Lists
Why is EBS up 3.67%?
Dive Deeper
EBS:NYSE
Emergent Biosolutions Inc
$ 7.06
+3.67%
(+0.25) 1D
$ 7.01
-0.71% (-0.050)
After hours
Closed: 10-р сарын 9, 16:00:07 (GMT-4)  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EBS...
Open
$ 6.73
High
$ 7.06
Low
$ 6.60
Mkt. cap
361.99 сая
Avg. vol.
1.18 сая
Volume
850.96 мян
52-wk high
$ 14.06
52-wk low
$ 4.36
EPS
-$ 3.51
Beta
2.28
Shares outstanding
51.27 сая
No. of employees
900
Open
$ 6.73
High
$ 7.06
Low
$ 6.60
Mkt. cap
361.99 сая
Avg. vol.
1.18 сая
Volume
850.96 мян
52-wk high
$ 14.06
52-wk low
$ 4.36
EPS
-$ 3.51
Beta
2.28
Shares outstanding
51.27 сая
No. of employees
900
News stories
From web sources and news partners
Profile
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes. Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid. During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded. Wikipedia
About Emergent Biosolutions Inc
CEORobert G. Kramer Sr. | Joseph C. Papa
Employees900
Founded1998 оны 9-р сарын 5
HeadquartersRockville, Мэрилэнд, Америкийн Нэгдсэн Улс
Sector-
Websiteemergentbiosolutions.com
Analyst ratings
Based on 2 analysts giving stock ratings to EBS in the past 3 months
Hold
Buy
1
Hold
0
Sell
1
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for EBS in the last 3 months.
Highest
Current $ 7.06
$ 10.00 (+41.64%)
Average
$ 10.00 (+41.64%)
Lowest
$ 10.00 (+41.64%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$ 10.00
+41.6%
09/09/2026
Jessica Fye
J.P. Morgan
Sell
Initiated
-
-
08/21/2026
Last report
2026 оны 8-р сарын 5
Fiscal period
Q2 2026
$ 0.60 / $ 0.11
+445.45%beat
Revenue / Est. (USD)
234.30 сая / 177.50 сая
+32.00%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 оны 9-р сар
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
Revenue
231.10 сая
148.70 сая
156.10 сая
234.30 сая
Cost of goods sold
99.00 сая
94.00 сая
82.40 сая
106.10 сая
Cost of revenue
99.00 сая
94.00 сая
82.40 сая
106.10 сая
Research and development expenses
200.00 мян
-600.00 мян
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
28.30 сая
61.60 сая
46.60 сая
44.60 сая
Operating expense
44.80 сая
77.30 сая
63.10 сая
61.80 сая
Total operating expenses
143.80 сая
171.30 сая
145.50 сая
167.90 сая
Operating income
87.30 сая
-22.60 сая
10.60 сая
66.40 сая
Other non operating income
-3.70 сая
-8.10 сая
13.90 сая
-
EBT including unusual items
57.60 сая
-50.70 сая
13.40 сая
-166.30 сая
EBT excluding unusual items
68.40 сая
-45.40 сая
13.50 сая
56.40 сая
Income tax expense
6.40 сая
3.90 сая
6.60 сая
13.90 сая
Effective tax rate
11.11%
-7.69%
49.25%
-8.36%
Other operating expenses
-
-
-
-
Net income
51.20 сая
-54.60 сая
6.80 сая
-180.20 сая
Net profit margin
22.15%
-36.72%
4.36%
-76.91%
Earnings per share
1.06
-0.43
0.21
0.60
Interest and investment income
-
-
-
-
Interest expense
-15.20 сая
-14.70 сая
-11.00 сая
-10.00 сая
Net interest expenses
-15.20 сая
-14.70 сая
-11.00 сая
-10.00 сая
Depreciation and amortization charges
-
-
-
-
EBITDA
110.30 сая
2.40 сая
33.50 сая
89.90 сая
Gain or loss from assets sale
2.20 сая
-11.20 сая
800.00 мян
11.90 сая
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google аппс